NashBio can improve clinical decision support tools and other healthcare products using AI trained on our real-world dataset, which contains abundant numbers of patient notes, images, electronic health records, and enriched phenotypes.
Improving AI-guided clinical decision support
Improving AI-guided clinical decision support
Overview
Challenge
Clinical decision support tools bring order to documentation and data in a patient’s electronic health record (EHR), which enables clinicians to work efficiently and improve patient outcomes. Such tools are particularly important for oncology patients, where time is critical and their care typically requires visits to multiple specialists who need to effectively communicate with one another. Artificial intelligence (AI) and machine learning (ML) will be used to enhance clinical decision support tools and protocols, especially for unstructured clinical notes and medical images.
One major challenge to developing these tools is they require datasets with large amounts of patients with specific diseases, as well as longitudinal EHRs, notes, and imaging data for training.
At a Glance
new cancer patients per year
patients with imaging data
prostate cancer patients
Data from
NCI-Designated Comprehensive Cancer Center
Our Impact
NashBio’s robust real-world data, coupled with our industry expertise, allow us to effectively guide clients to develop AI and ML tools that improve clinical decisions. For the case of oncology patients, our dataset is enriched in participants with different types of cancers and information related to pathological and clinical staging.
Our clinical and technical teams can work with clients to define cohorts that are ideal for training and then provide unstructured notes, images, and EHR data for AI and ML tool development. NashBio’s vast amount of images and notes makes our dataset ideal to leverage for AI studies.
Overall, we expect to significantly improve clinical decision making as well as other areas of healthcare that use AI and ML tools developed with our data.
Nashbio Differentiators
Curated Real World Data
Enriched Phenotypes
Industry Experts
Our Impact
NashBio’s robust real-world data, coupled with our industry expertise, allow us to effectively guide clients to develop AI and ML tools that improve clinical decisions. For the case of oncology patients, our dataset is enriched in participants with different types of cancers and information related to pathological and clinical staging.
Our clinical and technical teams can work with clients to define cohorts that are ideal for training and then provide unstructured notes, images, and EHR data for AI and ML tool development. NashBio’s vast amount of images and notes makes our dataset ideal to leverage for AI studies.
Overall, we expect to significantly improve clinical decision making as well as other areas of healthcare that use AI and ML tools developed with our data.
Nashbio Differentiators
Curated Real World Data
Enriched Phenotypes
Industry Experts
Identifying drug targets for pain relief
Read more >
Defining disease outcomes using real-world data
Read more >
Developing predictive diagnosis algorithms
Read more >